Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127615691 | 12761569 | 1 | I | 2015 | 20160913 | 20160920 | 20160920 | EXP | US-009507513-1609USA007101 | MERCK | 0.00 | E | F | Y | 108.80000 | KG | 20160920 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127615691 | 12761569 | 1 | PS | PROVENTIL | ALBUTEROL | 1 | 180 MICROGRAM, AS NECESSARY | 20503 | 180 | UG | INHALATION POWDER | ||||||||
| 127615691 | 12761569 | 2 | SS | EYLEA | AFLIBERCEPT | 1 | Intraocular | 2 MG, UNK | 2 | MG | 0 | 2 | MG | INJECTION | |||||
| 127615691 | 12761569 | 3 | SS | EYLEA | AFLIBERCEPT | 1 | Intraocular | 2 MG (PRESUMED) RIGHT EYE (OD), ONCE MONTHLY FOR 3 INJECTIONS THEN EVERY 2 MONTHS, INTRAOCULAR | 2 | MG | 0 | 2 | MG | INJECTION | /month | ||||
| 127615691 | 12761569 | 4 | SS | EYLEA | AFLIBERCEPT | 1 | Intraocular | 2 MG (PRESUMED) RIGHT EYE (OD), ONCE MONTHLY FOR 3 INJECTIONS THEN EVERY 2 MONTHS, INTRAOCULAR | 2 | MG | 0 | 2 | MG | INJECTION | /month | ||||
| 127615691 | 12761569 | 5 | SS | GABAPENTIN. | GABAPENTIN | 1 | UNK UNK, QD | 0 | QD | ||||||||||
| 127615691 | 12761569 | 6 | SS | GABAPENTIN. | GABAPENTIN | 1 | UNK | 0 | |||||||||||
| 127615691 | 12761569 | 7 | SS | SPIRIVA | TIOTROPIUM BROMIDE MONOHYDRATE | 1 | UNK, QD | 0 | QD | ||||||||||
| 127615691 | 12761569 | 8 | SS | ZYRTEC | CETIRIZINE HYDROCHLORIDE | 1 | 10 MG, QD | 0 | 10 | MG | QD | ||||||||
| 127615691 | 12761569 | 9 | C | ZETIA | EZETIMIBE | 1 | 0 | TABLET | |||||||||||
| 127615691 | 12761569 | 10 | C | HYZAAR | HYDROCHLOROTHIAZIDELOSARTAN POTASSIUM | 1 | 0 | TABLET |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127615691 | 12761569 | 1 | Product used for unknown indication |
| 127615691 | 12761569 | 2 | Neovascular age-related macular degeneration |
| 127615691 | 12761569 | 5 | Spinal column stenosis |
| 127615691 | 12761569 | 7 | Product used for unknown indication |
| 127615691 | 12761569 | 8 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127615691 | 12761569 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127615691 | 12761569 | Asthma | |
| 127615691 | 12761569 | Eosinophil count increased | |
| 127615691 | 12761569 | Pulmonary function test decreased | |
| 127615691 | 12761569 | Transient ischaemic attack |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127615691 | 12761569 | 2 | 20160524 | 0 | ||
| 127615691 | 12761569 | 3 | 20160621 | 20160621 | 0 | |
| 127615691 | 12761569 | 4 | 20160719 | 20160719 | 0 | |
| 127615691 | 12761569 | 5 | 201601 | 201602 | 0 | |
| 127615691 | 12761569 | 6 | 20160703 | 201607 | 0 |